In combination with our observations regarding the positive effects of p23 upon AR stabilisation and signalling, and also on cell aggressiveness and motility, this leads us to postulate that inhibiting p23 in combination with HSP90 could be an effective therapeutic combination against prostate cancer. Here, PTGES3 is linked to prostate cancer.